These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 30557370)

  • 1. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.
    Baas J; Krens L; Bohringer S; Mol L; Punt C; Guchelaar HJ; Gelderblom H
    PLoS One; 2018; 13(12):e0208080. PubMed ID: 30557370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
    Tol J; Koopman M; Rodenburg CJ; Cats A; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; Mol L; Antonini NF; Punt CJ
    Ann Oncol; 2008 Apr; 19(4):734-8. PubMed ID: 18272912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer.
    Kubo A; Hashimoto H; Takahashi N; Yamada Y
    World J Gastroenterol; 2016 Jan; 22(2):887-94. PubMed ID: 26811634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer.
    Pander J; van Huis-Tanja L; Böhringer S; van der Straaten T; Gelderblom H; Punt C; Guchelaar HJ
    PLoS One; 2015; 10(7):e0131091. PubMed ID: 26222057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
    Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr D; Gray V; West H; Houlston RS; Escott-Price V; Cheadle JP
    Int J Cancer; 2021 Nov; 149(9):1713-1722. PubMed ID: 34270794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
    Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
    Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
    Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
    Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).
    Labadie JD; Hua X; Harrison TA; Banbury BL; Huyghe JR; Sun W; Shi Q; Yothers G; Alberts SR; Sinicrope FA; Goldberg RM; George TJ; Penney KL; Phipps AI; Cohen SA; Peters U; Chan AT; Newcomb PA
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):404-411. PubMed ID: 33203692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.
    Petrelli F; Ardito R; Ghidini A; Zaniboni A; Ghidini M; Barni S; Tomasello G
    Oncology; 2018; 94(4):191-199. PubMed ID: 29393280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: how much does it cost? A retrospecive economic assessment from a single-center experience.
    Giuliani J; Indelli M; Marzola M; Raisi E; Frassoldati A
    Tumori; 2012; 98(4):408-12. PubMed ID: 23052154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
    Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
    JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
    Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V
    Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
    Rothschild SI; Betticher D; Zenhäusern R; Anchisi S; von Moos R; Pless M; Moosmann P; Popescu RA; Calderoni A; Dressler M; Rauch D; Pederiva S; Woelky R; Papet C; Bühler V; Borner M
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):881-889. PubMed ID: 31444619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
    Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
    Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
    Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
    Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
    Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
    Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.